재생의료 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 치료 카테고리별, 지역별, 부문 예측(2025-2030년)

Regenerative Medicine Market Growth & Trends:

The global regenerative medicine market size is expected to reach USD 90.01 billion by 2030, expanding at a CAGR of 16.83% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson's disease treatment. This approval was expected to expand the company's offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Report Highlights:

• The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
• The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
• Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
• North America dominated the market in 2024 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
• Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
• By therapeutic category, the oncology segment dominated the segment in 2024 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Therapeutic Category
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
  • 3.2.1. Market Dynamics
    • 3.2.1.1. Presence of a strong pipeline and a large number of clinical trials
    • 3.2.1.2. High economic impact of regenerative medicine
    • 3.2.1.3. Emerging applications of gene therapy in regenerative medicine
    • 3.2.1.4. Increasing government & private funding to support the development of regenerative medicine
    • 3.2.1.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
    • 3.2.1.6. Increase in strategic partnerships to accelerate the development & commercialization of regenerative medicines
    • 3.2.1.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to a rise in demand for regenerative treatments
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Regulatory issues pertaining to stem cells, tissue engineering, and regenerative medicines
• 3.3. Business Environment Analysis
  • 3.3.1. PESTEL Analysis
  • 3.3.2. Porter's Five Forces Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Regenerative Medicine Market: Product Movement Analysis
• 4.3. Therapeutics
  • 4.3.1. Therapeutics Market, 2018 - 2030 (USD Million)
  • 4.3.2. Primary Cell-Based Therapeutics
    • 4.3.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
    • 4.3.2.2. Dermatology
      • 4.3.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
    • 4.3.2.3. Musculoskeletal
      • 4.3.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
    • 4.3.2.4. Surgical
      • 4.3.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
    • 4.3.2.5. Dental
      • 4.3.2.5.1. Dental Market, 2018 - 2030 (USD Million)
    • 4.3.2.6. Others
      • 4.3.2.6.1. Others Market, 2018 - 2030 (USD Million)
  • 4.3.3. Stem Cell & Progenitor Cell-based therapeutics
    • 4.3.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
    • 4.3.3.2. Autologous
      • 4.3.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
    • 4.3.3.3. Allogenic
      • 4.3.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
    • 4.3.3.4. Others
      • 4.3.3.4.1. Others Market, 2018 - 2030 (USD Million)
  • 4.3.4. Cell-based Immunotherapies
    • 4.3.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
  • 4.3.5. Gene Therapies
    • 4.3.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
• 4.4. Tools
  • 4.4.1. Tools Market, 2018 - 2030 (USD Million)
• 4.5. Banks
  • 4.5.1. Banks Market, 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Category Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Regenerative Medicine Market: Therapeutic Category Movement Analysis
• 5.3. Dermatology
  • 5.3.1. Dermatology Market, 2018 - 2030 (USD Million)
• 5.4. Musculoskeletal
  • 5.4.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
• 5.5. Immunology & Inflammation
  • 5.5.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Oncology Market, 2018 - 2030 (USD Million)
• 5.7. Cardiovascular
  • 5.7.1. Cardiovascular Market, 2018 - 2030 (USD Million)
• 5.8. Ophthalmology
  • 5.8.1. Ophthalmology Market, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

• 6.1. Global Regenerative Medicine Market Share By Region, 2024 & 2030
• 6.2. North America
  • 6.2.1. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. Key Country Dynamics
    • 6.2.2.2. Competitive Scenario
    • 6.2.2.3. Regulatory Framework
    • 6.2.2.4. U.S. Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.2.3. Canada
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Competitive Scenario
    • 6.2.3.3. Regulatory Framework
    • 6.2.3.4. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.2.4. Mexico
    • 6.2.4.1. Key Country Dynamics
    • 6.2.4.2. Competitive Scenario
    • 6.2.4.3. Regulatory Framework
    • 6.2.4.4. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 6.3. Europe
  • 6.3.1. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.2. Germany
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.3. UK
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. UK Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.4. France
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Competitive Scenario
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.5. Italy
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Competitive Scenario
    • 6.3.5.3. Regulatory Framework
    • 6.3.5.4. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.6. Spain
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Competitive Scenario
    • 6.3.6.3. Regulatory Framework
    • 6.3.6.4. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.7. Denmark
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Competitive Scenario
    • 6.3.7.3. Regulatory Framework
    • 6.3.7.4. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.8. Sweden
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Competitive Scenario
    • 6.3.8.3. Regulatory Framework
    • 6.3.8.4. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3.9. Norway
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Competitive Scenario
    • 6.3.9.3. Regulatory Framework
    • 6.3.9.4. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.3. China
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.4. India
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.5. South Korea
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.6. Australia
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4.7. Thailand
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5.3. Argentina
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 6.6. MEA
  • 6.6.1. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6.4. UAE
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6.5. Kuwait
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Company Profiles/Listing
  • 7.4.1. AstraZeneca plc.
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. F. Hoffmann-La Roche Ltd.
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Integra Lifesciences Corp.
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Astellas Pharma, Inc.
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Cook Biotech, Inc.
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Bayer AG
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Pfizer, Inc.
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Merck KGaA
    • 7.4.8.1. Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Abbott
    • 7.4.9.1. Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Vericel Corp.
    • 7.4.10.1. Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives
  • 7.4.11. Novartis AG
    • 7.4.11.1. Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. GlaxoSmithKline
    • 7.4.12.1. Overview
    • 7.4.12.2. Financial Performance
    • 7.4.12.3. Product Benchmarking
    • 7.4.12.4. Strategic Initiatives